Ligand Pharmaceuticals Incorporated
LGNYZ
Other OTC0.04
USD
-0.01
- -
Ligand Pharmaceuticals Incorporated
LGNYZ
(Other OTC)
Recent
price
0.04
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ligand Pharmaceuticals Incorporated is a biopharmaceutical company specializing in acquiring, developing, and licensing royalty-generating pharmaceutical assets and proprietary drug development technology platforms. The company offers a diversified portfolio of biopharmaceutical programs that span multiple therapeutic areas including oncology, rare diseases, kidney disease, diabetes, nonalcoholic steatohepatitis, and vaccines. Its core products and services include commercial royalty rights to pharmaceutical products such as Kyprolis and Evomela for multiple myeloma; Rylaze, a recombinant erwinia asparaginase for acute lymphoblastic leukemia; Filspari, a dual endothelin and angiotensin II receptor antagonist for rare kidney diseases; Teriparatide injections for osteoporosis; and vaccines like Vaxneuvance and Pneumosil for pneumococcal disease prevention. Ligand also licenses its proprietary Captisol® and NITRICIL™ technology platforms which enhance drug solubility, stability, and delivery. Recent major changes include the acquisition of APEIRON Biologics AG in 2024 for $100 million, which added the commercial oncology drug QARZIBA (dinutuximab beta) used for treating high-risk neuroblastoma, marketed in 35 countries through a partnership with Recordati S.p.A. Ligand simultaneously committed up to $4 million in invIOs Holding AG, a spin-off of APEIRON, to support immuno-oncology research. In 2023, Ligand also acquired all assets related to the NITRICIL technology platform and the dermatology drug ZELSUVMI from Novan, Inc. Further, Ligand's subsidiary Pelthos Therapeutics entered a merger agreement in mid-2025, with Ligand investing $18 million in the combined entity to support growth. For fiscal 2025, Ligand set guidance projecting significant earnings per share growth, supported by robust revenue increases driven by its extensive royalty portfolio and commercial partnerships. Founded in 1987 and headquartered in San Diego, California, Ligand operates globally with economic rights to over 90 pharmaceutical products marketed in more than 70 countries. It maintains strategic alliances with leading pharmaceutical firms including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International, optimizing late-stage drug development, regulatory management, and commercialization. Ligand provides capital investment, drug development technology licensing, and portfolio management, focusing on advancing innovative medicines through collaboration, maintaining a comprehensive and geographically diverse industry presence. This broad approach positions Ligand as a key technology and capital partner in the biopharma sector, with a growing and diverse royalty revenue base complemented by continual business development and strategic acquisitions that expand its therapeutic reach and pipeline assets. The company is publicly traded on NASDAQ under the ticker LGND.